IN8BIO, Inc.
INAB- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001740279
No open-market purchases or sales by IN8BIO, Inc. insiders were filed in the last 90 days; 21 institutions reported holding it in 13F filings for Q2 2026, worth $5.35M in total; no superinvestor holds it.
Q4 2023 vs. Q3 2023
How the institutions holding IN8BIO, Inc. changed between Q3 2023 and Q4 2023.
All holders in Q4 2023All holders in Q3 2023
| Measure | Q3 2023 | Q4 2023 | Change |
|---|---|---|---|
| Holders | 21 | 30 | +9 |
| Shares | 2.48M | 8.58M | +6.11M (+246.5%) |
| Value | $2.58M | $11.4M | +$8.82M (+342.5%) |
New holders (9)
Institutions that held IN8BIO, Inc. at the end of Q4 2023 but not at the end of Q3 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| AIGH Capital Management LLC | 4,098,361 | $5.22M | 2.06% |
| Alyeska Investment Group, L.P. | 819,672 | $1.12M | 0.01% |
| 683 Capital Management, LLC | 614,754 | $848.4K | 0.08% |
| Two Sigma Investments, LP | 42,326 | $58.4K | 0.00% |
| Laird Norton Trust Company, LLC | 42,300 | $58.4K | 0.01% |
| Citadel Advisors LLC | 19,807 | $27.3K | 0.00% |
| Renaissance Technologies LLC | 19,578 | $27.0K | 0.00% |
| Vontobel Holding Ltd. | 10,000 | $13.9K | 0.00% |
| Bank of America Corp | 13 | $18 | 0.00% |
Sold out (0)
Institutions that held IN8BIO, Inc. at the end of Q3 2023 and filed for Q4 2023 without it.
None.